Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waverley Pharmaceuticals

Latest From Waverley Pharmaceuticals

Waverley Lists In Frankfurt

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.

Strategy Commercial

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Tech Transfer Deals Deals

Waverley Expands UK Cancer Portfolio

Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.

Cancer United Kingdom

Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma

Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register